
prof. dr. P.G.M. (Peter) Mol


Peter Mol is professor of drug regulatory science at the University Medical Center Groningen. His research focus is on developing new tools to support regulatory decision-making and the exchange of knowledge between regulatory authorities, health care professionals and lay people. He is currently involved in projects around personalized medicine, new data sources (RWE), patient-centric ways to weigh drug benefit-risk; e.g., using Patient Relevant Outcomes, Quality of Life, and Patient Preference information, and on risk communication; e.g., Direct Healthcare Provider Communication.
He is also a principal assessor at the Dutch Medicines Evaluation Board and a member (vice chair 2016-2022) of EMA’s Scientific Advice Working Party. He has coordinated over 250 scientific advice procedures, providing EMA advice on diabetes, cardiovascular, gynaecological and hematology programs. He is chair of the EMA Cross-Committee Task force on Registries (http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000658.jsp&mid=WC0b01ac0580961211).
Last modified: | 25 June 2022 02.32 a.m. |